awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33400687-5A048ACA-A0A8-4D4A-8514-E3A2DC1FF2AD
Q33400687-5A048ACA-A0A8-4D4A-8514-E3A2DC1FF2AD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33400687-5A048ACA-A0A8-4D4A-8514-E3A2DC1FF2AD
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer
P2860
Q33400687-5A048ACA-A0A8-4D4A-8514-E3A2DC1FF2AD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33400687-5A048ACA-A0A8-4D4A-8514-E3A2DC1FF2AD
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
d8069a562e6007fd46b10935ed64316db8c58cde
P2860
Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival.